Research
Hormonal
SGLT2 inhibitors reduce blood glucose and body weight in prediabetic patients by increasing urinary glucose excretion, effectively delaying diabetes development.
SGLT2 inhibitors (like dapagliflozin) lower blood sugar by excreting glucose in urine. They help with weight loss and delay diabetes. Side effects include increased risk of genital yeast infections and ketoacidosis. Monitor kidney function.
GoodSupportsHIGH confidence
SGLT2 inhibitors reduce SGLT2 activity and the efficiency of glucose uptake in the proximal tubules of the kidney, which increases the urinary glucose concentration and reduces blood glucose. ... SGLT2 inhibitors delayed the development of diabetes in four randomized trials involving 5655 patients with prediabetes
Why this rating
Supported by multiple randomized trials.
Source
Metabolic disorders in prediabetes: From mechanisms to therapeutic management
Wen-Xin Ping et al. · World Journal of Diabetes · 2024
DOI 10.4239/wjd.v15.i3.361
narrative_reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin is the most effective pharmacological intervention for preventing type 2 diabetes in prediabetic patients, significantly reducing diabetes incidence and improving glucose tolerance compared to lifestyle interventions alone.Good
- GLP-1 receptor agonists (GLP-1RAS) significantly reduce body weight and improve glucose tolerance in prediabetic patients, offering a potent alternative to metformin, particularly for those with obesity.Good
- Vitamin D supplementation (≥ 1000 IU/day) reduces the risk of developing diabetes in individuals with prediabetes by improving insulin sensitivity and beta-cell function.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →